Kendall Capital Management United Therapeutics Corp Transaction History

Kendall Capital Management

$316 Million
Q3 2024

A detailed history of Kendall Capital Management transactions in United Therapeutics Corp stock. As of the latest transaction made, Kendall Capital Management holds 6,542 shares of UTHR stock, worth $2.48 Million. This represents 0.74% of its overall portfolio holdings.

Number of Shares

6,542

Previous 6,202 5.48%

Holding current value

$2.48 Million

Previous $1.98 Million 18.68%

% of portfolio

0.74%

Previous 0.67%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$311.04 - $363.55 $105,753 - $123,607	340 Added 5.48%	6,542 $2.34 Million
Q2 2024 Aug 12, 2024	BUY	$228.26 - $319.04 $125,543 - $175,472	550 Added 9.73%	6,202 $1.98 Million
Q1 2024 May 10, 2024	BUY	$210.76 - $249.51 $303,494 - $359,294	1,440 Added 34.19%	5,652 $1.3 Million
Q4 2023 Jan 26, 2024	BUY	$214.88 - $256.94 $281,492 - $336,591	1,310 Added 45.14%	4,212 $926,000
Q3 2023 Oct 31, 2023	BUY	$211.82 - $248.24 $329,803 - $386,509	1,557 Added 115.76%	2,902 $655,000
Q2 2023 Jul 28, 2023	BUY	$205.19 - $232.99 $275,980 - $313,371	1,345 New	1,345 $297,000
Q4 2018 Feb 13, 2019	SELL	$101.4 - $128.73 $171,366 - $217,553	-1,690 Closed	0 $0
Q3 2018 Oct 29, 2018	SELL	$113.81 - $129.46 $175,836 - $200,015	-1,545 Reduced 47.76%	1,690 $216,000
Q2 2018 Jul 27, 2018	SELL	$101.14 - $118.31 $128,953 - $150,845	-1,275 Reduced 28.27%	3,235 $366,000
Q1 2018 May 14, 2018	BUY	$107.21 - $151.94 $13,401 - $18,992	125 Added 2.85%	4,510 $507,000
Q4 2017 Feb 14, 2018	BUY	$118.58 - $151.28 $519,973 - $663,362	4,385	4,385 $649,000

Others Institutions Holding UTHR

# of Institutions

672

Shares Held

42.4M

Call Options Held

194K

Put Options Held

295K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $17.3B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kendall Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Kendall Capital Management with notifications on news.

Account

Kendall Capital Management United Therapeutics Corp Transaction History